Shore invests $6M in healthcare AI data startup

H1 says it is the first to arm biopharmas with live data insights
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NEW YORK—H1, which touts itself as the first company to arm healthcare organizations with live data insights to help fight diseases, announced in late 2018 that Shore Group had invested $6 million to accelerate H1’s growth.
 
H1 says it has built a technology infrastructure grounded in machine intelligence that enables it to quickly find and surface relevant data from any public clinical and scholarly database anywhere in the world. The company “layers in” curated data harvested from hundreds of thousands of website profiles and conference presentations. According to H1, the result is that what used to take a healthcare organization a month to find and analyze—if they could find it at all—now takes just hours.
 
Ariel Katz, co-founder of H1, came to Shore Group when the company acquired his startup Labspot in 2016. He had a vision for a data company focused solely on healthcare, and Shore Group encouraged him to start H1 in late 2017.
 
“H1 has been very successful in developing technology that surfaces hard-to-find healthcare data and arms clients with that data so they can make better and faster data-driven decisions along their development pipeline,” said Ian Sax, CEO of Shore Group. “Ariel has opened our eyes to the big opportunities in healthcare data, and we are excited to continue to invest in H1.”
 
Added Katz: “With expertise in data collection for some of the largest global financial institutions, Shore Group was the ideal incubation spot for H1, as we established ourselves in the healthcare data space. Now that we are on solid footing, with a clear path to growth, we’re excited to operate independently, with Shore Group’s backing as an investor.”

Related Topics

Published In

Volume 15 - Issue 2 | February 2019

February 2019

February 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue